Apogee Therapeutics
APGE
Performance
About Apogee Therapeutics
Apogee Therapeutics is a clinical-stage biotechnology company focused on developing differentiated biologics for immunological and inflammatory diseases, including atopic dermatitis, COPD, and asthma. The company aims to reshape current standards of care by targeting well-established biological drivers with novel antibody therapeutics, addressing high unmet need in dermatology, respiratory, and other inflammatory conditions. Headquartered around the U.S. biopharma ecosystem, Apogee advances its pipeline through preclinical and clinical programs with a patient-centered focus.
Recent News
Wedbush Boosts Apogee Therapeutics to Outperform, Sets $135 Target Amid $1.3 B Blackstone Deal
Blackstone Commits up to $1.3bn to Apogee’s Skin Drug
Blackstone Commits up to $1.3 Billion to Fund Apogee Therapeutics' Zumilokibart Program
Blackstone Backs Apogee’s Atopic Dermatitis Therapy as It Heads to Phase III